Shares of Galapagos NV (NASDAQ:GLPG) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $102.50.

Several research analysts have weighed in on GLPG shares. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Wednesday, March 22nd. Instinet started coverage on Galapagos NV in a research report on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price objective on the stock. Nomura started coverage on Galapagos NV in a research report on Wednesday, March 1st. They issued a “buy” rating on the stock. Cowen and Company reissued a “buy” rating on shares of Galapagos NV in a research report on Wednesday, June 21st. Finally, BTIG Research reissued a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Tuesday, June 20th.

A number of hedge funds and other institutional investors have recently bought and sold shares of GLPG. Tower Research Capital LLC TRC acquired a new position in Galapagos NV during the first quarter valued at $161,000. Bank of Montreal Can boosted its position in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares in the last quarter. Cim Investment Mangement Inc. acquired a new position in Galapagos NV during the first quarter valued at $203,000. Karp Capital Management Corp acquired a new position in Galapagos NV during the first quarter valued at $206,000. Finally, Airain ltd acquired a new position in Galapagos NV during the first quarter valued at $237,000. 19.94% of the stock is currently owned by institutional investors and hedge funds.

Shares of Galapagos NV (NASDAQ GLPG) traded down 1.68% during midday trading on Tuesday, reaching $75.08. The company’s stock had a trading volume of 158,608 shares. The stock has a market cap of $3.47 billion, a PE ratio of 728.93 and a beta of 1.77. Galapagos NV has a one year low of $49.43 and a one year high of $94.88. The firm has a 50-day moving average of $83.52 and a 200-day moving average of $75.77.

COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Given Average Rating of “Buy” by Analysts” was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/06/27/galapagos-nv-glpg-given-average-rating-of-buy-by-analysts.html.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.